{"id":"sox-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Stomatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"S-1 is a prodrug of 5-fluorouracil that inhibits thymidylate synthase and incorporates into DNA/RNA, while oxaliplatin is a platinum agent that forms DNA cross-links. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells. This combination is commonly used in gastric and colorectal cancers.","oneSentence":"SOX is a combination chemotherapy regimen that uses S-1 (an oral fluoropyrimidine) and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:51.829Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer"},{"name":"Colorectal cancer"},{"name":"Esophageal cancer"}]},"trialDetails":[{"nctId":"NCT07492615","phase":"PHASE2","title":"A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-29","conditions":"Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":276},{"nctId":"NCT07474324","phase":"PHASE2","title":"Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-15","conditions":"GC/GEJC","enrollment":124},{"nctId":"NCT07464756","phase":"PHASE2","title":"SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-04-05","conditions":"Gastric Adenocarcinoma","enrollment":80},{"nctId":"NCT06461910","phase":"PHASE2","title":"Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Zekuan Xu","startDate":"2024-06-14","conditions":"Gastric Cancer, Esophagogastric Junction Adenocarcinoma","enrollment":30},{"nctId":"NCT07023315","phase":"PHASE3","title":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-08-14","conditions":"Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":760},{"nctId":"NCT07401199","phase":"","title":"Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)","status":"NOT_YET_RECRUITING","sponsor":"Qun Zhao","startDate":"2026-02-05","conditions":"Gastric Cancer (GC), Locally Advanced Gastric Cancer","enrollment":2000},{"nctId":"NCT06510010","phase":"PHASE2","title":"Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-12-31","conditions":"Chemotherapy Effect","enrollment":198},{"nctId":"NCT06761846","phase":"PHASE2","title":"Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-01-17","conditions":"Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma","enrollment":70},{"nctId":"NCT06468280","phase":"PHASE2","title":"Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-11-08","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":84},{"nctId":"NCT07353684","phase":"PHASE2","title":"Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-05-11","conditions":"Adebrelimab, Adenocarcinoma of GE Junction, Adenocarcinoma of Stomach","enrollment":49},{"nctId":"NCT07325630","phase":"PHASE2","title":"Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-11-03","conditions":"IBI363 + Chemotherapy","enrollment":60},{"nctId":"NCT07315854","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-11-04","conditions":"Gastric Cancer (GC), Gastroesophageal Junction Cancer, Advanced Gastric Cancer","enrollment":32},{"nctId":"NCT07315035","phase":"PHASE2","title":"QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-01-01","conditions":"Gastric Cancer Stage III","enrollment":74},{"nctId":"NCT06576921","phase":"PHASE2","title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-11-15","conditions":"Stomach Neoplasms, Immune Checkpoint Inhibitors","enrollment":116},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT07263386","phase":"PHASE2","title":"A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-10-23","conditions":"Gastric Adenocarcinoma","enrollment":460},{"nctId":"NCT07257380","phase":"PHASE2","title":"Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT07072351","phase":"PHASE1, PHASE2","title":"Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-09-15","conditions":"Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy","enrollment":88},{"nctId":"NCT07243938","phase":"PHASE2","title":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-15","conditions":"Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC)","enrollment":70},{"nctId":"NCT06826079","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-11-01","conditions":"Gastric Junction Adenocarcinoma, Gastric Cancer, Immunotherapy","enrollment":80},{"nctId":"NCT07161453","phase":"PHASE4","title":"Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2025-09-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":500},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":"Gastric Adenocarcinoma, Stomach Neoplasms","enrollment":54},{"nctId":"NCT07151209","phase":"PHASE2","title":"Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":20},{"nctId":"NCT07149181","phase":"PHASE4","title":"Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2025-08-31","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":1000},{"nctId":"NCT07148427","phase":"PHASE2","title":"Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-20","conditions":"Gastric/Gastroesophageal Junction Adenocarcinoma","enrollment":40},{"nctId":"NCT07132528","phase":"PHASE4","title":"Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2025-08-31","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":1000},{"nctId":"NCT07127822","phase":"PHASE2","title":"Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2025-09-01","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer","enrollment":106},{"nctId":"NCT07098949","phase":"NA","title":"Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2025-08","conditions":"Gastric Cancer","enrollment":346},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT03636893","phase":"PHASE2","title":"Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2018-08-24","conditions":"Gastric Cancer, Chemotherapy Effect","enrollment":74},{"nctId":"NCT06427252","phase":"PHASE2","title":"The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-05-31","conditions":"Gastric Cancer, Metastatic","enrollment":50},{"nctId":"NCT07068516","phase":"PHASE3","title":"Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xiangdong Cheng","startDate":"2025-07-20","conditions":"Gastric Cancer Stage","enrollment":470},{"nctId":"NCT06949033","phase":"PHASE3","title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Zuoyi Jiao","startDate":"2025-05-15","conditions":"Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy","enrollment":668},{"nctId":"NCT07056010","phase":"NA","title":"Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-11-25","conditions":"Gastric Cancer","enrollment":30},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT06939439","phase":"PHASE3","title":"Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-01","conditions":"Gastric Cancer Stage III","enrollment":416},{"nctId":"NCT07034742","phase":"EARLY_PHASE1","title":"Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-01","conditions":"Gastric Adenocarcinoma","enrollment":136},{"nctId":"NCT05161572","phase":"PHASE2","title":"Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer","status":"TERMINATED","sponsor":"Fudan University","startDate":"2021-09-28","conditions":"Stomach Neoplasms, Esophagogastric Junction Disorder, Neoadjuvant Therapy","enrollment":6},{"nctId":"NCT07025889","phase":"PHASE1, PHASE2","title":"IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-02","conditions":"Gastric Cancer","enrollment":55},{"nctId":"NCT05170503","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-12-29","conditions":"Esophagogastric Junction Adenocarcinoma","enrollment":37},{"nctId":"NCT07018063","phase":"PHASE2","title":"Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"zhoujing","startDate":"2025-10-01","conditions":"Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced","enrollment":35},{"nctId":"NCT06346093","phase":"NA","title":"Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2024-04-02","conditions":"Advanced Gastric Cancer","enrollment":124},{"nctId":"NCT06440811","phase":"","title":"Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2021-01-01","conditions":"Immune-related Adverse Event, Chemotherapeutic Toxicity, Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":120},{"nctId":"NCT07000253","phase":"PHASE2, PHASE3","title":"Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2026-01","conditions":"Esophageal Cancer, Gastric (Stomach) Cancer, Gastric Adenocarcinoma","enrollment":290},{"nctId":"NCT06963593","phase":"PHASE4","title":"Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2025-06-01","conditions":"Advanced Gastroesophageal Cancer","enrollment":220},{"nctId":"NCT06925243","phase":"PHASE3","title":"Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Zuoyi Jiao","startDate":"2025-04-15","conditions":"Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy","enrollment":682},{"nctId":"NCT06685887","phase":"PHASE2","title":"A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-02-15","conditions":"Gastric Cancer","enrollment":34},{"nctId":"NCT05593458","phase":"PHASE3","title":"Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2023-04-01","conditions":"Locally Advanced Gastric Carcinoma","enrollment":190},{"nctId":"NCT06914687","phase":"PHASE2","title":"Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-03-30","conditions":"Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis","enrollment":30},{"nctId":"NCT06888037","phase":"PHASE2","title":"Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-03-31","conditions":"Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy","enrollment":55},{"nctId":"NCT06405113","phase":"PHASE2","title":"FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Changzhou No.2 People's Hospital","startDate":"2024-06-01","conditions":"Gastric Cancer","enrollment":198},{"nctId":"NCT06829797","phase":"PHASE2","title":"A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined with SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2025-02-28","conditions":"Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","enrollment":96},{"nctId":"NCT03662659","phase":"PHASE2","title":"An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-10-16","conditions":"Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction","enrollment":274},{"nctId":"NCT05180734","phase":"PHASE3","title":"PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-02-10","conditions":"Gastric or Esophagogastric Junction Adenocarcinoma","enrollment":878},{"nctId":"NCT06774222","phase":"PHASE2","title":"A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2023-09-12","conditions":"Gastric/Gastroesophageal Junction Adenocarcinoma","enrollment":69},{"nctId":"NCT06766578","phase":"PHASE2","title":"Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2024-12-31","conditions":"Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","enrollment":32},{"nctId":"NCT06157216","phase":"NA","title":"Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-10-01","conditions":"Stage II-III Gastric Cancer","enrollment":85},{"nctId":"NCT06760858","phase":"","title":"A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Southwest Hospital, China","startDate":"2024-12-01","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":122},{"nctId":"NCT02867839","phase":"PHASE3","title":"Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer","status":"TERMINATED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2017-04-24","conditions":"Gastric Cancer","enrollment":29},{"nctId":"NCT06682182","phase":"","title":"Tislelizumab Combined with SOX and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Metastasis: a Prospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Southwest Hospital, China","startDate":"2024-12-01","conditions":"Gastric Cancer with Peritoneal Metastasis","enrollment":74},{"nctId":"NCT06662110","phase":"","title":"IMmune Proteomics to Predict NeoAdjuvant Chemotherapy and ImmunoTherapy Response in Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-08-01","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":206},{"nctId":"NCT06459921","phase":"PHASE2","title":"Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-12-01","conditions":"Neoadjuvant Chemotherapy, Sintilimab, Locally Advanced Gastric Cancer","enrollment":200},{"nctId":"NCT06597227","phase":"PHASE4","title":"Proximal Gastrectomy Vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Guihua Wang","startDate":"2024-03-01","conditions":"Locally Advanced Gastric Cancer","enrollment":404},{"nctId":"NCT02969122","phase":"NA","title":"Treatment Strategy for Stage IV Gastric Cancer with Positive Peritoneal Cytology As the Only Non-curable Factor","status":"TERMINATED","sponsor":"Peking University","startDate":"2016-11","conditions":"Stomach Neoplasm","enrollment":59},{"nctId":"NCT06564298","phase":"PHASE2","title":"A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08","conditions":"Stomach Neoplasms","enrollment":39},{"nctId":"NCT06525714","phase":"EARLY_PHASE1","title":"Effect of HIPEC After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2024-08","conditions":"Gastric Cancer, Survival Rate","enrollment":302},{"nctId":"NCT06496789","phase":"PHASE2","title":"Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-27","conditions":"Gastric Adenocarcinoma","enrollment":35},{"nctId":"NCT06196697","phase":"PHASE2","title":"AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer","status":"RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-04-10","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":50},{"nctId":"NCT06464601","phase":"","title":"A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Wuhan University","startDate":"2025-04-01","conditions":"Gastric Cancer","enrollment":70},{"nctId":"NCT06451211","phase":"PHASE2","title":"Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-17","conditions":"Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach","enrollment":53},{"nctId":"NCT06447636","phase":"PHASE2","title":"Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-08-01","conditions":"Gastric Cancer, Gastro Esophageal Junction Cancer","enrollment":20},{"nctId":"NCT06419140","phase":"PHASE2","title":"Multimodal Rehabilitation on Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-06-01","conditions":"Gastric Cancer","enrollment":138},{"nctId":"NCT02746796","phase":"PHASE2, PHASE3","title":"Study of ONO-4538 in Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2016-03","conditions":"Gastric Cancer","enrollment":680},{"nctId":"NCT06374901","phase":"PHASE2","title":"Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.","status":"NOT_YET_RECRUITING","sponsor":"Xiangdong Cheng","startDate":"2024-04-25","conditions":"Gastric Cancer","enrollment":134},{"nctId":"NCT06371586","phase":"PHASE2","title":"Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-03-01","conditions":"Gastric Cancer, Diffuse Type Carcinoma","enrollment":67},{"nctId":"NCT05540145","phase":"","title":"Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-05-01","conditions":"Gastric Cancer","enrollment":70},{"nctId":"NCT06284746","phase":"PHASE2","title":"Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Lin Chen","startDate":"2023-10-01","conditions":"Locally Advanced Gastric Carcinoma, HER2 Negative, Efficacy","enrollment":80},{"nctId":"NCT06250894","phase":"PHASE2","title":"Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-03-30","conditions":"PD-1, Neoadjuvant Chemoradiotherapy, Gastroesophageal Junction Cancer","enrollment":32},{"nctId":"NCT06238167","phase":"PHASE2","title":"Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2024-04-01","conditions":"Gastric Cancer","enrollment":40},{"nctId":"NCT06235164","phase":"","title":"The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2019-01-01","conditions":"Locally Advanced Gastric Cancer","enrollment":585},{"nctId":"NCT06213519","phase":"PHASE2","title":"HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2024-02-20","conditions":"Peritoneal Metastases, Gastric Cancer","enrollment":69},{"nctId":"NCT05872685","phase":"PHASE2","title":"Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)","status":"RECRUITING","sponsor":"Yu jiren","startDate":"2023-12-24","conditions":"Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair","enrollment":314},{"nctId":"NCT06194981","phase":"","title":"Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-01-11","conditions":"Gastric Cancer","enrollment":260},{"nctId":"NCT06202781","phase":"","title":"Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2022-07-01","conditions":"Gastric Cancer, Tumor Microenvironment, Immunotherapy","enrollment":28},{"nctId":"NCT03607656","phase":"PHASE2, PHASE3","title":"The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2018-06-08","conditions":"Gastric Cancer Stage IIIB, Gastric Cancer Stage IIIC","enrollment":270},{"nctId":"NCT06158919","phase":"NA","title":"A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-11-20","conditions":"Gastric Cancer/Adenocarcinoma of Esophagogastric Junction","enrollment":58},{"nctId":"NCT05960955","phase":"PHASE2","title":"Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-11-13","conditions":"Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT06121700","phase":"PHASE2","title":"Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-01-01","conditions":"Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer","enrollment":55},{"nctId":"NCT06123455","phase":"PHASE2","title":"Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Tang-Du Hospital","startDate":"2023-08-01","conditions":"Gastric Cancer","enrollment":60},{"nctId":"NCT06118658","phase":"PHASE2","title":"Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2023-11-01","conditions":"Gastric, Colorectal Adenocarcinoma","enrollment":30},{"nctId":"NCT02338518","phase":"PHASE3","title":"Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients","status":"UNKNOWN","sponsor":"Jinling Hospital, China","startDate":"2015-01-04","conditions":"Stomach Neoplasms, Gastric Cancer","enrollment":297},{"nctId":"NCT04250948","phase":"PHASE2","title":"Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-10-12","conditions":"Gastric Cancer, Locally Advanced Solid Tumor","enrollment":108},{"nctId":"NCT05970627","phase":"PHASE2","title":"Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Yu jiren","startDate":"2023-07-28","conditions":"Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma","enrollment":30},{"nctId":"NCT05729646","phase":"PHASE2","title":"Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Yu jiren","startDate":"2023-05-31","conditions":"Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency","enrollment":90},{"nctId":"NCT05888675","phase":"EARLY_PHASE1","title":"Clinical Study of Weifuchun Treatment on Gastric Cancer","status":"COMPLETED","sponsor":"ShuGuang Hospital","startDate":"2016-07-01","conditions":"Gastric Cancer (Diagnosis)","enrollment":72},{"nctId":"NCT05948449","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2023-07","conditions":"Gastric Cancer","enrollment":37},{"nctId":"NCT05908838","phase":"EARLY_PHASE1","title":"Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer","status":"COMPLETED","sponsor":"ShuGuang Hospital","startDate":"2017-01-01","conditions":"Gastric Cancer (Diagnosis)","enrollment":146},{"nctId":"NCT05687357","phase":"PHASE2","title":"Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-03-15","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer","enrollment":140},{"nctId":"NCT05774964","phase":"PHASE2","title":"Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2023-03-15","conditions":"For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method","enrollment":100},{"nctId":"NCT05742620","phase":"NA","title":"Adjuvant Treatment of Digestive Tract Tumors","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2023-06-20","conditions":"Adjuvant Treatment","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":69,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SOX"],"phase":"marketed","status":"active","brandName":"SOX Chemotherapy","genericName":"SOX Chemotherapy","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SOX chemotherapy is a treatment for gastric cancer, specifically used in a study called RESONANCE-II, which combines the chemotherapy drug with S-1 and is administered in different cycles. The mechanism of SOX chemotherapy involves acting as a granulocyte colony-stimulating factor receptor agonist, a type of protein modality.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}